CN111655340A - 用于调节自噬的方法和药物组合物 - Google Patents

用于调节自噬的方法和药物组合物 Download PDF

Info

Publication number
CN111655340A
CN111655340A CN201880060882.7A CN201880060882A CN111655340A CN 111655340 A CN111655340 A CN 111655340A CN 201880060882 A CN201880060882 A CN 201880060882A CN 111655340 A CN111655340 A CN 111655340A
Authority
CN
China
Prior art keywords
dbi
amino acid
autophagy
subject
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880060882.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·克洛伊梅
J·M·布拉沃-桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paris Public Relief
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Cite
Original Assignee
Paris Public Relief
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paris Public Relief, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Universite de Paris filed Critical Paris Public Relief
Publication of CN111655340A publication Critical patent/CN111655340A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
CN201880060882.7A 2017-09-20 2018-09-19 用于调节自噬的方法和药物组合物 Pending CN111655340A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306229 2017-09-20
EP17306229.0 2017-09-20
PCT/EP2018/075286 WO2019057742A1 (en) 2017-09-20 2018-09-19 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF AUTOPHAGIA

Publications (1)

Publication Number Publication Date
CN111655340A true CN111655340A (zh) 2020-09-11

Family

ID=60009555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880060882.7A Pending CN111655340A (zh) 2017-09-20 2018-09-19 用于调节自噬的方法和药物组合物

Country Status (5)

Country Link
US (5) US20200268837A1 (https=)
EP (1) EP3684471A1 (https=)
JP (1) JP7330174B2 (https=)
CN (1) CN111655340A (https=)
WO (1) WO2019057742A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115990159A (zh) * 2023-02-16 2023-04-21 中山大学 阿曲生坦或其药学上可接收的盐在制备治疗肌肉萎缩侧索硬化症产品中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4013883A1 (en) * 2019-08-16 2022-06-22 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
CN118922206A (zh) * 2022-02-08 2024-11-08 国家医疗保健研究所 乙酰辅酶a结合蛋白的中和赋予自噬依赖性器官保护
EP4309733A1 (en) * 2022-07-22 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
EP4698185A1 (en) * 2023-04-18 2026-02-25 Osasuna Therapeutics SA Methods and systems for improving anti-cancer therapies
WO2025134073A2 (en) * 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating diseases or conditions induced by corticosteroids, synovial inflammation, and degenerative joint disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025436A2 (en) * 1999-10-05 2001-04-12 Curagen Corporation Endozepine-like polypeptides and polynucleotides encoding same
US20160250249A1 (en) * 2013-10-03 2016-09-01 Inserm ( Institute National De Lasanté Et De La Re Cherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2758189C (en) 2009-04-10 2020-12-29 Association Institut De Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025436A2 (en) * 1999-10-05 2001-04-12 Curagen Corporation Endozepine-like polypeptides and polynucleotides encoding same
US20160250249A1 (en) * 2013-10-03 2016-09-01 Inserm ( Institute National De Lasanté Et De La Re Cherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AGNIESZKA SIEJKA等: "Reduced plasma level of diazepam-binding inhibitor (DBI) in patients with morbid obesity" *
DAMIEN LANFRAY等: "Gliotransmission and Brain Glucose Sensing: Critical Role of Endozepines" *
ELISA CONTI等: "Reduced fasting plasma levels of diazepam-binding inhibitor in adolescents with anorexia nervosa" *
JEAN-CLAUDE DO REGO: "Pharmacological Characterization of the Receptor Mediating the Anorexigenic Action of the Octadecaneuropeptide: Evidence for an Endozepinergic Tone Regulating Food Intake" *
KOUHEI KAWAGUCHI等: "Subcellular localization of acyl-CoA binding protein in Aspergillus oryzae is regulated by autophagy machinery" *
MATSUDA等: "Effect of the diazepam-binding inhibitor-derived peptide, octadecaneuropeptide, on food intake in goldfish" *
ROHIT A SINHA等: "Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice" *
YING LI等: "Diazepam-binding inhibitor mediates feedback regulation of pancreatic secretion and postprandial release of cholecystokinin" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115990159A (zh) * 2023-02-16 2023-04-21 中山大学 阿曲生坦或其药学上可接收的盐在制备治疗肌肉萎缩侧索硬化症产品中的应用
CN115990159B (zh) * 2023-02-16 2024-05-17 中山大学 阿曲生坦或其药学上可接收的盐在制备治疗肌肉萎缩侧索硬化症产品中的应用

Also Published As

Publication number Publication date
JP7330174B2 (ja) 2023-08-21
US20230142694A1 (en) 2023-05-11
US20200268837A1 (en) 2020-08-27
WO2019057742A1 (en) 2019-03-28
EP3684471A1 (en) 2020-07-29
US20240245750A1 (en) 2024-07-25
US20260097094A1 (en) 2026-04-09
US11905330B1 (en) 2024-02-20
JP2020534337A (ja) 2020-11-26
US12343376B2 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
US12343376B2 (en) Methods for inhibiting diazepam binding protein
US20220168419A1 (en) Compositions and methods for treating autoimmune diseases and cancers
CN114133450B (zh) 抗-Rho GTPase的构象单域抗体及其用途
US9926562B2 (en) Methods for preventing and treating chronic kidney disease (CKD)
US11236147B2 (en) Methods and compositions for the inhibition of TRPV4
CA2805267A1 (en) Detection and treatment of fibrosis
US20140093494A1 (en) Alpha synuclein toxicity
WO2013017656A1 (en) Antagonists of ribonucleases for treating obesity
US12303515B2 (en) PIM1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof
JP2016088926A (ja) Ｉｋａｒｏｓ阻害に基づく抗炎症薬
WO2018115083A1 (en) Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
JP2025077049A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
JP2024537874A (ja) Ａｄａｍｔｓ１４阻害
WO2024107827A1 (en) Therapeutic exploitation of sting channel activity
AU2022379455A1 (en) Methods of treating the effects of cytokine storms
Class et al. Patent application title: Diagnosis and treatment of kidney stones, methods and compositions therefor Inventors: Jianghui Hou (Saint Louis, MO, US) Yongfeng Gong (Saint Louis, MO, US) Assignees: WASHINGTON UNIVERSITY
WO2017013270A1 (en) Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2015147575A1 (ko) Trpc4의 억제제를 유효성분으로 포함하는 발기부전 치료용 약제학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: G. Chloe may

Inventor after: J. M. Bravo San Pedro

Inventor before: G. Chloe may

Inventor before: J. M. Bravo San

CB03 Change of inventor or designer information
CB02 Change of applicant information

Address after: Paris France

Applicant after: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Applicant after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant after: SORBONNE UNIVERSITE

Applicant after: University of Western dais, Paris

Address before: Paris France

Applicant before: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Applicant before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant before: SORBONNE UNIVERSITE

Applicant before: University of Paris

CB02 Change of applicant information